Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Low Dose Tamoxifen +/- High Dose Omega-3 Fatty Acids for Breast Cancer Prevention
NCT06195306Phase 2Recruiting
- Sponsor
- National Cancer Institute
- Start
- Jul 2025
- Primary completion
- Jan 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of omega-3-acid triglycerides in breast cancer, sponsored by National Cancer Institute. Started Jul 2025; status: recruiting.
02
Drugs
omega-3-acid triglycerides
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT06195306.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06195306.